Tiotropium versus placebo for chronic obstructive pulmonary disease

Author:

Karner Charlotta1,Chong Jimmy2,Poole Phillippa3

Affiliation:

1. BMJ; BMJ-TAG; Tavistock Square London UK WC1H 9JR

2. University of Auckland; Auckland New Zealand

3. University of Auckland; Department of Medicine; Private Bag 92019 Auckland New Zealand

Publisher

Wiley

Subject

Pharmacology (medical)

Reference236 articles.

1. Bateman ED A randomised, double-blind, placebo-controlled, parallel-group study to assess long term (one-year) efficacy and safety of tiotropium inhalation solution 5 mcg (2 puffs of 2.5 mcg) delivered by the Respimat® inhaler in patients with chronic obstructive pulmonary disease (COPD) www.trials.boehringer-ingelheim.com

2. A one-year trial of tiotropium Respimat plus usual therapy in COPD patients;Bateman;Respiratory Medicine,2010

3. Efficacy and safety of tiotropium Respimat SMI in COPD in two 1-year randomized studies;Bateman;International Journal of Chronic Obstructive Pulmonary Disease,2010

4. Cooper C A retrospective collection of vital status and pulmonary medication usage data for patients with chronic obstructive pulmonary disease (COPD) who withdrew prematurely from either of two one-year trials (205.254, 205.255) of tiotropium inhalation solution delivered by the Respimat® inhaler www.trials.boehringer-ingelheim.com

5. Lack of paradoxical bronchoconstriction after administration of tiotropium via Respimat Soft Mist Inhaler in COPD;Hodder;International Journal of Chronic Obstructive Pulmonary Disease,2011

同舟云学术

1.学者识别学者识别

2.学术分析学术分析

3.人才评估人才评估

"同舟云学术"是以全球学者为主线,采集、加工和组织学术论文而形成的新型学术文献查询和分析系统,可以对全球学者进行文献检索和人才价值评估。用户可以通过关注某些学科领域的顶尖人物而持续追踪该领域的学科进展和研究前沿。经过近期的数据扩容,当前同舟云学术共收录了国内外主流学术期刊6万余种,收集的期刊论文及会议论文总量共计约1.5亿篇,并以每天添加12000余篇中外论文的速度递增。我们也可以为用户提供个性化、定制化的学者数据。欢迎来电咨询!咨询电话:010-8811{复制后删除}0370

www.globalauthorid.com

TOP

Copyright © 2019-2024 北京同舟云网络信息技术有限公司
京公网安备11010802033243号  京ICP备18003416号-3